MRI provides superior imaging for diverse clinical applications, but cost and other factors limit availability in various healthcare and lower resource settings. Low-field strength units promise to expand access but involve trade-offs including reduced signal, longer acquisitions, and uncertain benefit of contrast agents. Here we characterize T1 and T2 properties of ferumoxytol, an iron oxide agent with prolonged blood pool phase and higher R1 and R2 values than gadolinium, on a 64mT portable system. We demonstrate enhancement across a range of concentrations in phantoms and visualization of cerebral vasculature in patients receiving the agent for iron-deficiency anemia.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords